Manumycin A (52665-74-4) inhibits ras farnesyltransferase1 and prevents ras signaling2. Irreversibly inhibits neutral sphingomyelinase3. Abrogates IL-1β-induced HIF-1α activation in both glioma and non-glioma tumor cells4. Ameliorates acetaminophen-induced liver injury in mice5. Induces apoptosis and displays antiproliferative activity in various models3. Cell permeable.
1) Hara et al. (1993), Identification of Ras Farnesyltransferase inhibitors by microbial screening; Proc. Natl. Acad. Sci. USA, 90 2281
2) DiPaolo et al. (2000), Maunumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells; Br. J. Cancer, 82 905
3) Arenz et al. (2001), Manumycin A and its analogies are irreversible inhibitors of neutral sphingomyelinase; Chem. Bio. Chem., 2 141
4) Sharma et al. (2012), Farnesyltransferase inhibitor manumycin targets IL1β-Ras-HIF-1α axis in tumor cells of diverse origin; Inflammation, 35 516
5) Saha and Nandi (2009), Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice; Hepatology, 50 1547
6) Singha et al. (2013), Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death; Cell Death Dis., 4 e457